VIDEO: Corneal endothelial cell therapy achieves primary endpoint

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

The trial achieved its primary endpoint with statistical significance, according to Kunst, with 50% of patients in the high-dose arm gaining at least three lines of vision. He also highlighted the study’s secondary endpoints, all of which were achieved.

“We will be starting our phase 3 trials later this year,” Kunst said.

Published by:

Sources/Disclosures

Collapse

Source:

Goldstein M. Aurion Biotech. Healio | OSN’s disruptive innovations. Presented at: Hawaiian Eye 2025; Jan. 18-24, 2025; Koloa, Hawaii.

Disclosures:
Kunst reports being CEO of Aurion Biotech.

Read more about

This post was originally published on this site